Caribou Biosciences, Inc. (CRBU) stock
CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3073% below fair value
$0.35−0.01 (-2.51%)
Close on Nov 16, 2026Market cap $37.82MP/E –Yield –
Caribou Biosciences enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Caribou Biosciences's enterprise value was -$72.39M on Nov 11, 2026, against $22.13M a year earlier. Over the last 5 years it ranged from -$197.78M to $470.41M, with a median of $23.46M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$72.39M | – |
| 2025 | Dec 31, 2025 | -$10.59M | – |
| 2024 | Dec 31, 2024 | -$137.02M | -224.6% |
| 2023 | Dec 29, 2023 | $110.01M | +172.3% |
| 2022 | Dec 30, 2022 | $40.40M | -91.4% |
| 2021 | Dec 31, 2021 | $470.41M | – |
See a number that looks wrong?